NIH grant funds study of cerebral small vessel disease
Researchers at WashU Medicine have received $7.5 million from the National Institutes of Health (NIH) to investigate a form of dementia caused by cerebral small vessel disease, the second-leading cause of dementia after Alzheimer’s.
$10.8 million grant supports cutting-edge leukemia research
WashU Medicine has received renewal of a prestigious National Cancer Institute grant. Led by Daniel Link, MD, it provides funding for translational research into new therapies for patients with blood cancers.
Gratitude inspires generous support for WashU Medicine’s neurosurgery department
In recognition of a $50 million gift from Andrew and Barbara Taylor, the neurosurgery department at WashU Medicine has been named the Taylor Family Department of Neurosurgery.
Brain tumors hijack circadian clock to grow
Glioblastoma is an aggressive, incurable brain cancer that is the most common malignant brain tumor in adults. New research from Washington University in St. Louis shows that glioblastoma has an internal clock and syncs its daily rhythms to match — and take advantage of — the rhythms of its host.
Grant will fund development of vaccines to prevent dementia
Researchers at Washington University are looking to find new ways to design vaccines to protect against inflammation in the brain that causes dementia.
WashU Medicine reaches all-time high in NIH funding
WashU Medicine secured $683 million in research funding from the National Institutes of Health (NIH) in 2024, placing the school at No. 2 in NIH funding nationwide for the second year in a row.
WashU Medicine funded to develop new postdoctoral training program
Burel R. Goodin, a professor of anesthesiology at WashU Medicine, has received more than $3 million from the National Institutes of Health (NIH) to support postdoctoral training.
Analyzing multiple mammograms improves breast cancer risk prediction
A new, artificial intelligence-based method of analyzing mammograms, developed by researchers at WashU Medicine, identified individuals at high risk of developing breast cancer more accurately than the standard, questionnaire-based method did.
New drug tested to reduce side effect of ‘half-matched’ stem cell transplants
Results from a clinical trial conducted at WashU Medicine showed adding the investigational drug itacitinib to standard care for “half-matched” stem cell transplantation may reduce rates of graft-versus-host disease.
Evers honored with mentoring award
The Foundation for Anesthesia Education and Research has announced that Alex Evers, MD, the Henry E. Mallinckrodt Professor of Anesthesiology at Washington University School of Medicine in St. Louis, will receive the foundation’s 2024 Mentoring Excellence in Research Award.
View More Stories